These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Formation of neutralizing antibodies in therapy of multiple sclerosis with interferon beta-1b. Practical procedure in suspected therapeutic failure]. Walther EU; Dang T; Hartung HP; Hohlfeld R Nervenarzt; 1997 Dec; 68(12):935-9. PubMed ID: 9465334 [TBL] [Abstract][Full Text] [Related]
6. An open-labelled assessment of adverse effects associated with interferon 1-beta in the treatment of multiple sclerosis. Logan-Clubb L; Stacy M J Neurosci Nurs; 1995 Dec; 27(6):344-7. PubMed ID: 8770778 [TBL] [Abstract][Full Text] [Related]
7. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet; 1998 Nov; 352(9139):1498-504. PubMed ID: 9820297 [TBL] [Abstract][Full Text] [Related]
8. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Jacobs LD; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Fischer JS; Goodkin DE; Granger CV; Simon JH; Alam JJ; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Pullicino PM; Scherokman BJ; Whitham RH Ann Neurol; 1996 Mar; 39(3):285-94. PubMed ID: 8602746 [TBL] [Abstract][Full Text] [Related]
9. [Therapy of multiple sclerosis with interferon-beta-1b. Educating the patient and managing side-effects]. Walther EU; Dietrich E; Hohlfeld R Nervenarzt; 1996 Jun; 67(6):452-6. PubMed ID: 8767199 [TBL] [Abstract][Full Text] [Related]
10. Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Rudick RA; Goodkin DE; Jacobs LD; Cookfair DL; Herndon RM; Richert JR; Salazar AM; Fischer JS; Granger CV; Simon JH; Alam JJ; Simonian NA; Campion MK; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Coats ME; Cohan SL; Dougherty DS; Kinkel RP; Mass MK; Munschauer FE; Priore RL; Whitham RH Neurology; 1997 Aug; 49(2):358-63. PubMed ID: 9270562 [TBL] [Abstract][Full Text] [Related]
11. Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. Pozzilli C; Bastianello S; Koudriavtseva T; Gasperini C; Bozzao A; Millefiorini E; Galgani S; Buttinelli C; Perciaccante G; Piazza G; Bozzao L; Fieschi C J Neurol Neurosurg Psychiatry; 1996 Sep; 61(3):251-8. PubMed ID: 8795595 [TBL] [Abstract][Full Text] [Related]
12. Treatment of relapsing-remitting multiple sclerosis with natural interferon beta: a multicenter, randomized clinical trial. Fernández O; Antiquëdad A; Arbizu T; Capdevíla A; de Castro P; Correa de Sa JC; García-Merino JA; Izquierdo G; Magalhaes A; Montalbán X Mult Scler; 1995; 1 Suppl 1():S67-9. PubMed ID: 9345404 [TBL] [Abstract][Full Text] [Related]
13. Interferon beta-1A for relapsing multiple sclerosis. Med Lett Drugs Ther; 1996 Jul; 38(979):63-4. PubMed ID: 8692073 [No Abstract] [Full Text] [Related]
14. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Cohen JA; Coles AJ; Arnold DL; Confavreux C; Fox EJ; Hartung HP; Havrdova E; Selmaj KW; Weiner HL; Fisher E; Brinar VV; Giovannoni G; Stojanovic M; Ertik BI; Lake SL; Margolin DH; Panzara MA; Compston DA; Lancet; 2012 Nov; 380(9856):1819-28. PubMed ID: 23122652 [TBL] [Abstract][Full Text] [Related]
15. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis. Petkau J; White R Mult Scler; 1997 Dec; 3(6):402. PubMed ID: 9493643 [No Abstract] [Full Text] [Related]
19. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Simon JH; Jacobs LD; Campion M; Wende K; Simonian N; Cookfair DL; Rudick RA; Herndon RM; Richert JR; Salazar AM; Alam JJ; Fischer JS; Goodkin DE; Granger CV; Lajaunie M; Martens-Davidson AL; Meyer M; Sheeder J; Choi K; Scherzinger AL; Bartoszak DM; Bourdette DN; Braiman J; Brownscheidle CM; Whitham RH Ann Neurol; 1998 Jan; 43(1):79-87. PubMed ID: 9450771 [TBL] [Abstract][Full Text] [Related]
20. Long-term benefits of early and high doses of interferon beta-1a treatment in relapsing-remitting multiple sclerosis. Chofflon M; Ben-Amor AF Clin Neurol Neurosurg; 2002 Jul; 104(3):244-8. PubMed ID: 12127662 [No Abstract] [Full Text] [Related] [Next] [New Search]